Griseofulvin Safety and Use in Children

Introduction to Griseofulvin

• Griseofulvin is safe and remains the only licensed oral antifungal agent for treating tinea capitis in children in the UK, with over 50 years of clinical experience demonstrating its safety profile, particularly in pediatric populations 1, 2

Licensing and Regulatory Status

• Griseofulvin is the only licensed product for treating tinea capitis in children in the UK, approved for use from 1 month of age 1, 2
• Griseofulvin is FDA-approved for children and is the only antifungal agent licensed for pediatric onychomycosis 3

Safety Profile in Children

• Side effects in children are generally mild and infrequent, with gastrointestinal disturbances and rashes occurring in less than 8% of patients, and only 0.8% requiring treatment discontinuation 1, 2

Dosing in Pediatric Populations

• The standard licensed dose is 20 mg/kg daily in single or divided doses for 6-8 weeks in children weighing less than 50 kg 1, 2
• Doses may be increased up to 25 mg/kg daily for prolonged periods in resistant cases 1, 2

Contraindications and Drug Interactions

• Contraindicated in children with lupus erythematosus, porphyria, or severe liver disease 1
• Important drug interactions include: plasma concentration decreased by rifampicin and increased by cimetidine 1

Efficacy Considerations by Organism

• Griseofulvin demonstrates 88.5% response rates for Microsporum species but only 67.9% for Trichophyton species, requiring higher doses (up to 25 mg/kg) and longer treatment durations (12-18 weeks) for Trichophyton infections 1, 2
• For Microsporum canis infections specifically, 8 weeks of griseofulvin treatment is significantly more effective than 4 weeks of terbinafine 1, 2

Practical Advantages for Pediatric Use

• Suspension formulations (where available) are more palatable to children and allow more accurate dosage adjustments based on weight 1, 2

Important Clinical Caveats

• Treatment duration is prolonged (6-8 weeks minimum, up to 12-18 weeks for Trichophyton), which may affect compliance—this is the primary disadvantage compared to newer agents 1, 2
• The definitive endpoint for adequate treatment must be mycological cure rather than clinical response alone; follow-up with repeat mycology sampling is recommended 4
• For anthropophilic species like Trichophyton tonsurans, screen and treat all family members, as over 50% may be affected, leading to high recurrence rates if untreated 4

Griseofulvin Use in Children – Guideline Recommendations

Dosage Recommendations

• The British Association of Dermatologists recommends initiating griseofulvin at 10 mg/kg per day (maximum 500 mg) for children aged 1 month and older. 5

Administration Advice

• Griseofulvin should be taken with a fatty meal to enhance absorption and improve bioavailability. 5

Off‑Label Use in the United States (Children < 2 years)

• When prescribing griseofulvin off‑label to children under 2 years in the U.S., clinicians should weigh the risk‑benefit ratio because no alternative licensed antifungal options exist for this age group. 5
• An informed‑consent discussion with parents (or guardians) must be documented when using griseofulvin off‑label in children under 2 years. 5